ロード中...
Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. Most of the patients of PDAC present at later stages of disease and have a five-year survival rate of less than 10%. About 5–10% PDAC cases are hereditary in nature and have DNA damage repair (DDR) mutations such as BRCA 1 and 2. B...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6966572/ https://ncbi.nlm.nih.gov/pubmed/31835379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11121980 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|